Pulmonary Arterial Hypertension (PAH) | Norton Healthcare

Indication: Pulmonary Arterial Hypertension (PAH)

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH

Sub-indication: Pulmonary Arterial Hypertension

Drug Study

Principal Investigator: John W. McConnell, M.D.
Norton Pulmonary Specialists

Sponsor: UNITED THERAPEUTICS CORPORATION

Learn more at ClinicalTrials.gov

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.